Core Insights - Bristol Myers Squibb (BMS) reported a total revenue of $48.194 billion for 2025, nearly flat compared to $48.300 billion in 2024, but achieved a significant turnaround in GAAP net profit from a loss of $8.948 billion in 2024 to a profit of $7.054 billion in 2025, with Non-GAAP net profit soaring over 430% from $2.340 billion to $12.545 billion [1][2] Group 1: Financial Performance - The growth product portfolio generated $26.409 billion in revenue, accounting for over 54.8% of total revenue, marking a 17% increase year-over-year [1][3] - Traditional products, including Revlimid and Pomalyst, saw a significant revenue decline of 15%, contributing only $21.785 billion [1][3] Group 2: Product Performance - Revlimid's sales plummeted nearly 49% to $2.951 billion, primarily due to generic competition, with Pomalyst also facing a 54% decline in international sales [3][4] - Eliquis generated $14.443 billion in sales, reflecting an 8% increase, with expectations of 10% to 15% growth in 2026 [4][8] Group 3: Strategic Initiatives - BMS completed five strategic transactions in 2025, including a notable $1.5 billion collaboration with BioNTech to develop a next-generation bispecific antibody [7][8] - The company is shifting its focus from a few blockbuster drugs to a diversified product matrix, with more products exceeding $1 billion in sales [6][8] Group 4: Future Outlook - BMS anticipates a revenue guidance of $46 billion to $47.5 billion for 2026, indicating a cautious outlook amid ongoing challenges from patent expirations [11] - The company is actively pursuing opportunities in cell therapy for autoimmune diseases and expects significant data readouts in 2026 for several key products [9][10]

Core Viewpoint - The recent round of national drug procurement has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas, with only 21 original drugs winning bids, representing less than 10% of the total [1][2]. Group 1: Procurement Details - The procurement aims to reduce drug prices and patient burdens while reallocating saved healthcare funds to innovative drugs that provide significant clinical value [2]. - The procurement process was led by the medical insurance bureaus of Jiangsu, Henan, and Guangdong provinces, with a high selection rate of 93% among participating companies [2]. - The results of this procurement are expected to be implemented by the end of March 2026, with a procurement cycle lasting until the end of 2028 [2]. Group 2: Original Drug Participation - The original drugs selected include various formulations such as Fosinopril and Acarbose, with companies like Bristol-Myers Squibb and Sanofi involved [3]. - Several original drugs that had previously won bids in earlier rounds, such as Gefitinib and Clopidogrel, did not participate in this round, allowing generic competitors to dominate [4][3]. - The absence of original drugs in the procurement reflects a trend where original drugs face significant competition from generics post-patent expiration, leading to a decline in sales and profits [6]. Group 3: Market Dynamics - The "patent cliff" phenomenon has led to original drugs experiencing substantial sales and profit declines once their patents expire, which was previously mitigated by high prices and market share [6]. - Some original drug companies have reduced or dissolved their sales teams for products affected by procurement policies, yet many still find market opportunities outside public hospital settings [7]. - Cross-national pharmaceutical companies are increasingly focusing on innovative drug development while divesting mature product lines to local firms [8][9]. Group 4: Future Outlook - The Chinese government is implementing policies to support the development of innovative drugs, which is expected to expand the overall pharmaceutical market [10].

Core Viewpoint - The recent round of national drug procurement has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas, with only 21 original drugs selected, representing less than 10% of the total [1][2]. Group 1: Procurement Details - The procurement aims to reduce drug prices and patient burdens while reallocating saved healthcare funds to innovative drugs [2]. - The procurement process involved 51,000 medical institutions, with a high selection rate of 93% and an average of 14 companies selected per product [2][3]. - The results of this procurement are expected to be implemented by the end of March 2026, with a procurement cycle lasting until the end of 2028 [2]. Group 2: Original Drug Participation - The selected original drugs include various formulations from companies like Bristol-Myers Squibb, Sanofi, and Bayer, with some previously shortlisted in earlier rounds [3]. - Notable original drugs that did not participate in this round include AstraZeneca's gefitinib and Sanofi's clopidogrel, which had previously been selected [4][3]. Group 3: Market Dynamics - The phenomenon known as "patent cliff" has led to significant declines in sales and profits for original drugs post-patent expiration, making it challenging for them to maintain market share without substantial price reductions [6]. - Some original drug companies have reduced or dissolved their sales teams for products affected by procurement policies, yet many still find market opportunities outside public hospital procurement [7]. - Cross-national pharmaceutical companies are increasingly focusing on innovative drug development while divesting mature product lines to local firms [8][9].

2026.02. 12 本文字数：2499，阅读时长大约4分钟 作者 | 第一财经 林志吟 近日，1至8批国家集采药品新一轮接续采购已诞生拟中选结果，共有1020家企业的4163个产品获 得拟中选资格，涉及316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、 呼吸系统、消化系统等26个治疗领域。 从这接续采购的316种药品来看，据第一财经记者统计，有原研药中标的品种共有21个，整体占比 不到一成。 不到一成的原研药中标 国家药品集采，针对的仿制药以及过了专利保护期的原研药这两大类产品，一方面，挤掉药价虚高的 水分，降低患者用药负担；另外一方面，通过集采节省下的医保资金，转向支付临床价值显著的创新 药，满足临床亟需，鼓励药企研发创新。 本次是针对1-8批国家集采药品新一轮接续采购，由江苏、河南、广东三省医保局联合牵头，各省份 全部参与，实现了采购规则规范统一。企业只需在线投标一次，中选即可实现全国销售。具备投标资 格的企业绝大多数参与投标报价，整体中选率高达93%，每个品种平均14家企业中选。 本次接续采购，国内药品上市许可持有人（含药品注册批件持有人）、境外药品上市许可持有人及其 境内责任 ...

凭借品牌优势在院外市场找到新的发展空间。 近日，1至8批国家集采药品新一轮接续采购已诞生拟中选结果，共有1020家企业的4163个产品获得拟中 选资格，涉及316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系 统、消化系统等26个治疗领域。 2018年以来，随着国家组织的药品集采启动，医药行业逐渐走向分水岭，过了专利保护期的原研药难以 在中国市场维持高利润且垄断局面，而原来以销售这类药物为生的跨国药企这几年已在密集调整业务， 重塑在华发展战略。 一些原研药虽然缺席集采，但并不意味着从市场消失，相反凭借品牌优势仍在院外市场找到新的发展空 间。 不到一成的原研药中标 国家药品集采，针对的仿制药以及过了专利保护期的原研药这两大类产品，一方面，挤掉药价虚高的水 分，降低患者用药负担；另外一方面，通过集采节省下的医保资金，转向支付临床价值显著的创新药， 满足临床亟需，鼓励药企研发创新。 本次是针对1-8批国家集采药品新一轮接续采购，由江苏、河南、广东三省医保局联合牵头，各省份全 部参与，实现了采购规则规范统一。企业只需在线投标一次，中选即可实现全国销售。具备投标资格的 企业绝大多数参与投标报价 ...

农历新年前，中国创新药企业达成的几笔交易，给经历一轮上涨又陷入漫长蛰伏的板块带来暖意。 2026年以来，中国创新药对外授权交易总金额在短短四十多天里已超过300亿美元，首付款规模已超去 年全年单季度最高水平。数字之外，创新药BD（业务拓展）模式的调整，也映射出了中国企业在产业 链中能力与角色的变迁。 即便MNC当前对中国创新药资产的主动性需求更强，且白宫回应称并未"积极考虑"该草案，但BD作为 中国企业当前发展逻辑的关键一环，变幻莫测的地缘政治因素仍然会掣肘中国创新药行业。 图片来源：视觉中国 上周末，信达生物与礼来制药宣布达成新一轮全球战略合作，双方将共同推进肿瘤及免疫领域创新药物 的全球研发。根据协议，信达生物将获得3.5亿美元首付款。在达成后续特定里程碑事件后，信达生物 还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。 这是这家中国创新药公司与礼来的第七次合作。与以往不同的是，本次合作并未围绕公司已有的成熟分 子展开，而是针对尚未成型的新想法，MNC（跨国制药巨头）是为信达生物的早期研发平台和效率付 费，进行"端到端"的全球研发共建。 信达生物将运用其抗体技术平台，主导药物的早期研发，至 ...

智通财经APP获悉，赛诺菲(SNY.US)于2月12日突然宣布首席执行官Paul Hudson下课，由默沙东 (MRK.US)集团高管贝伦·加里霍接任。这家法国制药巨头此前大幅加码研发投入，却迟迟未见成果，董 事会的耐心已然耗尽。截至发稿，该股盘前跌超6%。 Paul Hudson执掌赛诺菲六年有余，任内一直试图为重磅药物Dupixent寻找"接棒者"——这款哮喘及特应 性皮炎药物正面临专利悬崖，销售峰值过后收入将急转直下。然而关键布局屡屡落空：去年三项后期临 床实验结果混杂乃至失败，令股东失望情绪集中爆发。 "如果2020年你问我，赛诺菲需要五到七年吗?当时我斩钉截铁说不会。"Paul Hudson今年1月底在业绩会 上坦言，"我们更聪明、更强，一定能更快——可惜事与愿违。" 去年赛诺菲出清消费者健康业务控股权，意味着公司未来将完全依赖创新处方药。分析师约翰·墨菲、 米拉·班科夫斯卡娅评价称，Paul Hudson大幅重塑了这家曾被诟病"法式保守"的企业文化，提升其全球 站位，并规划出至2030年的盈利增长路径。然而，由于未能攻克研发效率痼疾、也未能为Dupixent找到 真正继任者，赛诺菲估值倍数始终跑输 ...

Core Insights - Major multinational pharmaceutical companies are showing robust revenue growth and increased sales of core products as they release their 2025 performance results [1][2] - Johnson & Johnson leads with nearly $94.2 billion in revenue, while Eli Lilly's weight loss drug, tirzepatide, shows a remarkable 45% year-over-year growth [1][2] Group 1: Revenue Performance - Johnson & Johnson reported total revenue of $94.193 billion for 2025, marking a 6% increase year-over-year [2] - Roche follows with revenue of $74.428 billion, while Eli Lilly, Merck, Pfizer, and AbbVie each exceeded $60 billion in revenue [2] - Eli Lilly's revenue reached $65.179 billion, a 44.7% increase, driven by strong sales of tirzepatide, which generated $36.5 billion [6] Group 2: Product Performance - Johnson & Johnson's innovative pharmaceuticals and medical technology segments both achieved revenue growth, with $60.401 billion and $33.792 billion respectively, both up by approximately 6% [2] - The CAR-T therapy, ciltacabtagene autoleucel, contributed significantly to Johnson & Johnson's growth, with revenue of $1.887 billion, a 95.9% increase [2] - Eli Lilly's tirzepatide sales reached $36.5 billion, with the weight loss version generating $13.542 billion, a 175% increase [6] Group 3: Market Trends and Challenges - The pharmaceutical industry faces a looming "patent cliff," with an estimated $236 billion in revenue at risk from patent expirations between 2025 and 2030 [8] - Companies are increasingly engaging in business development transactions to replenish their R&D pipelines, with Chinese innovative pharmaceutical companies gaining prominence [8][9] - In 2025, Chinese companies achieved record-breaking business development deals, totaling $135.655 billion, with significant collaborations involving major multinational firms [9]

Core Insights - Eli Lilly's tirzepatide is projected to surpass Novo Nordisk's semaglutide in global sales by 2025, claiming the title of "king of drugs" [1] - Eli Lilly reported a total revenue of $65.179 billion for 2025, a 44% year-over-year increase, with a net profit of $20.64 billion, up 95% [1] - Tirzepatide contributed over $36.5 billion in revenue, with sales of the diabetes version reaching $22.965 billion (99% increase) and the weight loss version at $13.542 billion (175% increase) [1] - Novo Nordisk's revenue for 2025 was approximately $48.95 billion, with semaglutide accounting for 73.9% of its revenue, totaling about $36.1 billion [1] Market Dynamics - The pharmaceutical industry is experiencing a shift in leadership, with the "king of drugs" title changing hands more frequently due to patent expirations [2] - Semaglutide's core patent will expire in March 2026, while tirzepatide's patent is expected to last until after 2030, but both are facing increased competition from generics [2] - A price war has begun, with both Eli Lilly and Novo Nordisk announcing price reductions for their key diabetes and weight loss drugs starting November 2025 [2][3] Future Projections - Eli Lilly anticipates total revenue of $80 billion to $83 billion for 2026, representing a 25% increase from 2025 [3] - Novo Nordisk has lowered its 2026 sales guidance, expecting a decline of 5% to 13% due to pricing pressures affecting its diabetes and weight loss drugs [3] - The global obesity treatment market is rapidly evolving, with over 600 drugs in development, primarily in the U.S. and China [3]

过去几年，GLP-1赛道成为医药行业内最受瞩目和最火热的领域之一。此前多位参加2026年摩根大通医 疗健康大会（J.P.Morgan Healthcare Conference，下称"JPM大会"）的受访者告诉时代财经，GLP-1及代 谢性领域是今年与会嘉宾讨论的热门话题。而礼来、诺和诺德、辉瑞（PFE.US）等多家跨国药企也均 在上述会议现场强调将持续深耕减重市场。 2025年，诺和诺德（NVO.US）实现净销售额3090.4亿丹麦克朗（约合489.5亿美元），明星大单品司美 格鲁肽为其贡献了73.9%的营收。2月4日，诺和诺德发布2025年全年财报，披露上述信息。 具体来看，司美格鲁肽全年销售额为2282.88亿丹麦克朗（约合361亿美元），其中，司美格鲁肽降糖注 射版Ozempic（中国商品名：诺和泰）销售额为1270.89亿丹麦克朗（约合201亿美元），同比增长 10%；降糖口服版Rybelsus（中国商品名：诺和忻）销售额为220.93亿丹麦克朗（约合35亿美元），同 比下滑2%；司美格鲁肽减重版Wegovy（中国商品名：诺和盈）销售额为791.06亿丹麦克朗（约合125亿 美元），同比增长41%， ...